Cerebrospinal fluid homovanillic acid is correlated to psychotic features in neurological patients with delirium

General Hospital Psychiatry

Volumn 30, Issue 4, 2008, Pages 337-343

  Ramirez Bermudez, Jesus ^a   Ruiz Chow, Angel ^a   Perez Neri, Ivan ^a   Soto Hernandez, Jose Luis ^a   Flores Hernandez, Ricardo ^a   Nente, Francisco ^a   Montes, Sergio ^a   Rios, Camilo ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Acute confusional state; Delirium; Dopamine; Homovanillic acid; Psychosis

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DELIRIUM; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC TRANSMISSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLITE; PSYCHOSIS; RATING SCALE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DELIRIUM; DELUSIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE; FEMALE; HALLUCINATIONS; HIV INFECTIONS; HOMOVANILLIC ACID; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SYNAPTIC TRANSMISSION;

EID: 45549095089     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2008.01.007     Document Type: Article

References (35)

1. Burns A., Gallagley A., and Byrne J. Delirium. J Neurol Neurosurg Psychiatry 75 (2004) 362-367
2. Meagher D.J., Moran M., Raju B., et al. Phenomenology of delirium: assessment of 100 adult cases using standardised measures. Br J Psychiatry 190 (2007) 135-141
3. Trzepacz P.T. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5 (2000) 132-148
4. Webster R., and Holroyd S. Prevalence of psychotic symptoms in delirium. Psychosomatics 41 (2000) 519-522
5. Han C.S., and Kim Y.K. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45 (2004) 297-301
6. Skrobik Y.K., Bergeron N., Dumont M., and Gottfried S.B. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 30 (2004) 444-449
7. Young C.C., and Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit. Anesthesiology 10 (2004) 794-795
8. Fujimoto A., Nagao T., Ebara T., Sato M., and Otsuki S. Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state. Biol Psychiatry 18 (1983) 1141-1152
9. van der Cammen T.J., Tiemeier H., Engelhart M.J., and Fekkes D. Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium. Int J Geriatr Psychiatry 21 (2006) 838-843
10. Ramirez-Bermudez J., Soto-Hernandez J.L., Lopez-Gomez M., et al. Frequency of neuropsychiatric signs and symptoms in patients with viral encephalitis. Rev Neurol 41 (2005) 140-144
11. Ramirez-Bermudez J., Lopez-Gomez M., Sosa A.L., et al. Frequency of delirium in a neurological emergency room. J Neuropsychiatry Clin Neurosci 18 (2006) 108-112
12. Trzepacz P.T., Baker R.W., and Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 23 (1988) 89-97
13. Secin R., Esponda J., and Rivera B. Validación del delirium rating scale (DRS) en español en una unidad de cuidados intensivos. Psiquis 7 (1998) 7-14
14. Mittal D., Jimerson N.A., Neely E.P., et al. Risperidone in the treatment of delirium: results from a prospective open-label trial. J Clin Psychiatry 65 (2004) 662-667
15. Meagher D.J., O'Hanlon D., O'Mahony E., Casey P.R., and Trzepacz P.T. Relationship between symptoms and motoric subtype of delirium. J Neuropsychiatry Clin Neurosci 12 (2000) 51-56
16. Montes S., Alcaraz-Zubeldia M., Muriel P., et al. Striatal manganese accumulation induces changes in dopamine metabolism in the cirrhotic rat. Brain Res 891 (2001) 123-129
17. You Z.B., Tzschentke T.M., Brodin E., and Wise R.A. Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats. J Neurosci 18 (1998) 6492-6500
18. Invernizzi R., Garavaglia C., and Samanin R. JL 13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn-Schmiedeberg's Arch Pharmacol 361 (2000) 298-302
19. Adachi Y.U., Yamada S., Satomoto M., et al. Isoflurane anesthesia induces biphasic effect on dopamine release in the rat striatum. Brain Res Bull 67 (2005) 176-181
20. Myin-Germeys I., Marcelis M., Krabbendam L., Delespaul P., and van Os J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 58 (2005) 105-110
21. Scheepers F.E., Gispen-de Wied C.C., Westenberg H.G., and Kahn R.S. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25 (2001) 468-475
22. Agren H., and Terenius L. Hallucinations in patients with major depression. Interactions between CSF monoaminergic and endorphinergic indices. J Affect Disord 9 (1985) 25-34
23. Gaudreau J.D., and Gagnon P. Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. Med Hypotheses 64 (2005) 471-475
24. Kozak R., Martinez V., Young D., et al. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology 32 (2007) 2074-2086
25. Cancelli I., Valentinis L., Merlino G., Valente M., and Gigli G.L. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther (2007) 10.1038/sj.clpt.6100435
26. Kahn R.S., Davidson M., Knott P., et al. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 50 (1993) 599-605
27. Schmitz Y., Benoit-Marand M., Gonon F., and Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87 (2003) 273-289
28. Zauli G., Secchiero P., Rodella L., et al. HIV-1 Tat-mediated Inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275 (2000) 4159-4165
29. Aksenova M.V., Silvers J.M., Aksenov M.Y., et al. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: Changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395 (2006) 235-239
30. Nilsson L.K., Nordin C., Jönsson E.G., et al. Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res 41 (2007) 144-151
31. Mayo-Smith M.F., Beecher L.H., Fischer T.L., et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch. Intern Med 164 (2004) 1408-1412
32. Caroff S.N., Mann S.C., McCarthy M., et al. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol 18 (1998) 349-351
33. Serrano-Duenas M. Neuroleptic malignant syndrome in patients with non-herpetic viral encephalitis. Study of 7 cases. Med Clin (Barc) 118 (2002) 62-64
34. Montoya A., Ocampo M., and Torres-Ruiz A. Neuroleptic malignant syndrome in Mexico. Can J Clin Pharmacol 10 (2003) 111-113
35. Zaragoza M., and Torres E. Olazapine induced neuroleptic malignant syndrome. Actas Esp Psiquiatr 34 (2006) 144-155